CA-AMAZENTIS
7.7.2022 14:09:09 CEST | Business Wire | Press release
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005266/en/
This study showed that treatment with Amazentis’ proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model.
These findings highlight Mitopure’s benefits for joint and mitochondrial health. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. This change is associated with age-related problems in various tissues, including osteoarthritis.
Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations. This new paper extends these benefits to cells in key joints such as the knee. Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.
“There are currently no effective solutions to treat osteoarthritis, a condition that is painful and limits the mobility of hundreds of millions of older people around the world. We tested Urolithin A in preclinical models of osteoarthritis and showed it has potential to both reduce inflammation and improve mitochondrial health, suggesting it may be a promising solution to support joint health and quality of life during aging,” says Martin Lotz MD, lead author on the paper and Professor of Molecular Medicine at Scripps Research in California, USA.
“This study is important and exciting as it shows, for the first time, that Urolithin A can increase mitochondrial health in living joint tissue,” says Davide D’Amico, first author on the paper and R&D Group Leader with Amazentis. “It highlights the important role of mitophagy in maintaining healthy functioning joints throughout life.”
In this study, Mitopure showed two key beneficial effects on cartilage cells from both healthy donors and OA patients:
- It significantly induced the recycling of aged and damaged mitochondria (mitophagy), assessed by imaging and molecular biology assays.
- It significantly increased the activity of mitochondria, measured as mitochondrial respiration, i.e. the ability of these organelles to consume oxygen and produce energy for our cells.
The second part of the study focused on the effect of supplementing Mitopure for 2 months on an experimental pre-clinical model of osteoarthritis. This model mimics the same symptoms experienced by people suffering from osteoarthritis, i.e. progressive cartilage damage, increased pain and inflammation.
- Analysis of knee joint sections by a pathologist indicated that supplementation with Mitopure decreased joint tissue degradation.
- Mitopure supplementation also reduced OA associated leg pain and exerted a mild anti-inflammatory effect on the disease model.
- Finally, better joint heath after Mitopure administration was associated with significantly enhanced mitochondrial health, including higher rates of removing worn out mitochondria (mitophagy) and increased regeneration of new, functional mitochondria.
"It was great to collaborate with Scripps Research to expand the body of evidence on the health applications of Urolithin A into joint health. It’s exciting to see a compound and mechanism of action that is benefiting both muscle and joints. We remain committed to delivering products that are clinically proven to have a meaningful impact on people’s health” says Chris Rinsch, CEO and co-founder of Amazentis.
The new results are significant because they add to growing evidence of the benefits of Mitopure on age-related conditions. Recent studies showed that Mitopure can improve mitochondrial health and counteract age-related muscle function decline in both healthy elderly and middle-aged overweight subjects. Together, the latest research supports a combined beneficial action of Urolithin A in both muscle and joints.
Doi: 10.1111/acel.13662
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure® Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279), Cell Reports Medicine
(Doi: 10.1016/j.xcrm.2022.100633) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure® linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure®
Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure® has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure® has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure® has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® is brought to you by the inventors of Mitopure®. This novel, science-first nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iQmetrix to Deliver 2026 Telecom Industry Address and Product Announcements, Unveiling the Next Wave of Intelligent Commerce14.9.2026 19:40:00 CEST | Press release
iQmetrix's annual industry briefing goes global on October 28, pairing a year of worldwide market intelligence with the company's outlook on AI-native commerce and a first look at what's next for its Intelligent Commerce Operating System iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, today opened registration for the 2026 Telecom Industry Address and Product Announcements, taking place Wednesday, October 28, 2026. For the first time in the event's history, iQmetrix will run two dedicated virtual sessions: one built specifically for European audiences, alongside its long-running North American event. Both are free to attend. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914992633/en/ Now in its seventh year, the Industry Address has become the telecom channel's annual checkpoint: an unfiltered read on where the market is heading, delivered by a company that sits at the intersection of
The Estée Lauder Companies Announces Partnership with Profound to Expand AI Visibility Across Its Global Brand Portfolio14.9.2026 18:32:00 CEST | Press release
Partnership enables the company to lead prestige beauty's transition to AI-powered discovery while better understanding how consumers discover, evaluate, and engage with its brands across AI answer engines The Estée Lauder Companies Inc. (NYSE: EL) today announced a global strategic partnership with Profound, the category-defining AI marketing platform, advancing its ambition to be prestige beauty’s leader in AI-native discovery. The partnership will provide the company with visibility into how its full portfolio of brands is represented across leading generative AI platforms, as well as opportunities to optimize that representation. This partnership establishes the company as the first in prestige beauty to deploy Profound’s capabilities globally across the company’s full portfolio and operationalize Generative Engine Optimization (GEO) and AI marketing at scale. As consumers increasingly turn to ChatGPT, Gemini, and other AI assistants to discover products, compare recommendations, a
AMAALA Yacht Club Opens, Putting the Red Sea on the Global Yachting Map14.9.2026 18:00:00 CEST | Press release
Luxury sailing, wellness and exploration converge at Saudi Arabia's newest yachting destination Red Sea Global (RSG), the regenerative tourism developer, has announced that AMAALA Yacht Club has officially begun operations, marking a major milestone in establishing the Saudi Red Sea as a new global destination for luxury yachting, sailing and marine tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914160771/en/ AMAALA Yacht Club, the new luxury yachting destination on Saudi Arabia’s Red Sea coast. Nestled within AMAALA Marina Village, the AMAALA Yacht Club is now welcoming founding members and visiting yachts to moor and explore the destination. Located approximately 2,000 nautical miles from Monaco, the club provides a new winter destination for the world’s luxury sailing community, which traditionally migrates from the Mediterranean to the Caribbean or Indian Ocean from October. Positioned closer to the Mediterra
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates14.9.2026 15:40:00 CEST | Press release
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914150232/en/ Students from Qatar, Canada and Mexico during their visit to the University of Toronto as part of the Doha Debates Town Hall experience in Canada. (Photo: AETOSWire) An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives. This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of sp
Matt Shafer Joins Golub Capital as Head of Golub Equity Continuation Partners14.9.2026 15:30:00 CEST | Press release
Golub Capital (“the Firm”) today announced the appointment of Matt Shafer as Managing Director and Head of the Firm’s GP-led private equity secondaries strategy, Golub Equity Continuation Partners (“GECP”). In this role, he will be responsible for leading the continued growth and development of the strategy and helping expand the Firm’s equity investment capabilities. Matt will work closely with Greg Cashman, Vice Chair and Co-Head of Golub Capital’s Sponsor Finance practice, to expand Golub Capital’s activity in this growing market. Shafer brings nearly three decades of global experience as an investor, financier and advisor working with private equity firms. He was most recently Head of Capital Solutions and U.S. Private Equity at Northleaf Capital Partners. In this role, Shafer helped lead the firm’s private equity investment activities, including secondaries, co‑investments and structured capital. Prior to Northleaf, he was Partner and Head of Americas Private Equity at Vision Capi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom